Healthmaterial’s liquid glass is a flexible material that can be used to treat patients with advanced cancers.
Eliminating the need for expensive surgery to remove cancerous material from a patient’s body would mean a quicker and more successful treatment.
The glass is currently used in cancer treatments at the University of Queensland, which is also one of the world’s largest centres for the development of liquid glass.
Professor Simon Moulton, the director of the Department of Bioengineering at the university, said the research could lead to a “super-biohacking” product that could be used in the treatment of many types of cancer.
“We could be creating a new way of looking at the biology of cancer and using that to treat disease,” he said.
“This is a very promising, novel approach to the treatment, and could lead, in time, to the creation of a new cancer drug.”‘
We don’t need to reinvent the wheel’It would also help reduce the number of treatments needed for cancer, Professor Moulson said.
Professor Moulon said the material could be made to last indefinitely and could be recycled into different types of glass and other materials.
“One of the challenges is that we don’t have any of the traditional manufacturing processes that we need to produce these materials,” he explained.
“It’s very difficult to get the materials to the point where they can be made into a product, and we don.
Treatment options”Professor Moulson said while there was already a range of liquid and glass treatments for cancer and other conditions, they could not be used together because there was too much material.”
There are very few ways to extract these materials, and most of those are either too costly or they are just not practical,” he told ABC News.
Professor Michael Molloy, the Chief Medical Officer of the Royal Australasian College of Surgeons, said a liquid glass treatment was “a very exciting and potentially exciting alternative to traditional chemo, radiotherapy and radiotherapy drugs”.
“If it can be scaled up and made available, it would help to reduce the amount of expensive and often invasive treatments for these conditions,” he added.
“That’s what we’re looking at in the UK.
We are looking at ways to improve the effectiveness of these drugs.”
Professor Molloya said while it was difficult to see how it would be commercially viable in Australia, it was possible the new treatment could be sold in Australia and used there.
“If the technology can be commercialised and commercialised in Australia as a treatment for certain types of cancers, it’s likely that it could be commercially successful there,” he advised.
“But it’s also likely that other countries will look at it and be more open to it.”
Professor Simon’s research has been funded by the National Health and Medical Research Council (NHMRC), the Australian Research Council and the Australian Institute of Health and Welfare.